Lazard Asset Management LLC Has $578.63 Million Position in Boston Scientific Co. (NYSE:BSX)

Lazard Asset Management LLC decreased its holdings in Boston Scientific Co. (NYSE:BSX - Free Report) by 10.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,478,233 shares of the medical equipment provider's stock after selling 775,800 shares during the quarter. Boston Scientific makes up approximately 0.8% of Lazard Asset Management LLC's holdings, making the stock its 28th largest holding. Lazard Asset Management LLC owned 0.44% of Boston Scientific worth $578,634,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently bought and sold shares of the company. TFC Financial Management Inc. grew its holdings in Boston Scientific by 308.8% during the 4th quarter. TFC Financial Management Inc. now owns 278 shares of the medical equipment provider's stock valued at $25,000 after purchasing an additional 210 shares in the last quarter. Colonial Trust Co SC grew its position in shares of Boston Scientific by 1,625.0% in the 4th quarter. Colonial Trust Co SC now owns 276 shares of the medical equipment provider's stock worth $25,000 after acquiring an additional 260 shares in the last quarter. West Oak Capital LLC acquired a new stake in shares of Boston Scientific during the fourth quarter worth $29,000. Valley National Advisers Inc. grew its position in shares of Boston Scientific by 262.4% during the 4th quarter. Valley National Advisers Inc. now owns 395 shares of the medical equipment provider's stock valued at $35,000 after buying an additional 286 shares during the last quarter. Finally, Fairway Wealth LLC acquired a new stake in shares of Boston Scientific during the 4th quarter worth approximately $36,000. Hedge funds and other institutional investors own 89.07% of the company's stock.

Analyst Ratings Changes

Several analysts recently weighed in on BSX shares. Wells Fargo & Company lifted their price objective on shares of Boston Scientific from $100.00 to $118.00 and gave the company an "overweight" rating in a research report on Thursday, February 6th. StockNews.com upgraded shares of Boston Scientific from a "hold" rating to a "buy" rating in a research report on Tuesday, April 29th. Truist Financial raised their price objective on Boston Scientific from $113.00 to $117.00 and gave the stock a "buy" rating in a research note on Thursday, April 24th. Stifel Nicolaus boosted their price target on shares of Boston Scientific from $100.00 to $115.00 and gave the company a "buy" rating in a report on Thursday, February 6th. Finally, Morgan Stanley raised their price objective on Boston Scientific from $100.00 to $120.00 and gave the stock an "overweight" rating in a research report on Thursday, February 6th. Twenty-three equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $114.52.

Boston Scientific Stock Performance

Shares of Boston Scientific stock traded up $1.68 during trading on Thursday, reaching $104.63. The company's stock had a trading volume of 6,940,176 shares, compared to its average volume of 6,358,493. The business's fifty day moving average price is $98.76 and its 200-day moving average price is $96.28. Boston Scientific Co. has a one year low of $71.88 and a one year high of $107.17. The firm has a market cap of $154.79 billion, a price-to-earnings ratio of 83.70, a price-to-earnings-growth ratio of 2.79 and a beta of 0.68. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.02 and a current ratio of 1.08.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings data on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.08. The company had revenue of $4.66 billion for the quarter, compared to the consensus estimate of $4.57 billion. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. The business's revenue was up 20.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.56 EPS. As a group, equities research analysts predict that Boston Scientific Co. will post 2.85 earnings per share for the current year.

Insider Activity

In other news, SVP Vance R. Brown sold 4,826 shares of the business's stock in a transaction on Monday, April 21st. The stock was sold at an average price of $95.09, for a total transaction of $458,904.34. Following the completion of the sale, the senior vice president now owns 36,193 shares in the company, valued at $3,441,592.37. The trade was a 11.77% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Michael F. Mahoney sold 164,443 shares of the stock in a transaction that occurred on Thursday, May 1st. The shares were sold at an average price of $102.48, for a total transaction of $16,852,118.64. Following the completion of the transaction, the chief executive officer now owns 1,535,706 shares in the company, valued at $157,379,150.88. This represents a 9.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 267,021 shares of company stock worth $27,534,636. 0.50% of the stock is currently owned by corporate insiders.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.